Literature DB >> 16306627

Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity.

David Perez-Caballero1, Theodora Hatziioannou, Fengwen Zhang, Simone Cowan, Paul D Bieniasz.   

Abstract

TRIM-CypA is an owl monkey-specific variant of the retrovirus restriction factor TRIM5alpha. Here, we exploit its modular domain organization and cyclosporine sensitivity to probe the kinetics and mechanism of TRIM5-mediated restriction. Time of addition/withdrawal experiments reveal that inhibition of incoming human immunodeficiency virus type 1 capsids by TRIM-CypA occurs within minutes of their delivery to the target cell cytoplasm. However, while TRIM-CypA restriction is partly dependent on a RING domain, restriction occurs independently of the ubiquitin/proteasome system. Moreover, tagged TRIM-CypA proteins can be fully active as restriction factors without forming cytoplasmic bodies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16306627      PMCID: PMC1316013          DOI: 10.1128/JVI.79.24.15567-15572.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  A Trim5-cyclophilin A fusion protein found in owl monkey kidney cells can restrict HIV-1.

Authors:  Sébastien Nisole; Clare Lynch; Jonathan P Stoye; Melvyn W Yap
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

Review 2.  Retrovirus restriction factors.

Authors:  Stephen P Goff
Journal:  Mol Cell       Date:  2004-12-22       Impact factor: 17.970

Review 3.  Intrinsic immunity: a front-line defense against viral attack.

Authors:  Paul D Bieniasz
Journal:  Nat Immunol       Date:  2004-11       Impact factor: 25.606

4.  Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells.

Authors:  Brett M Forshey; Jiong Shi; Christopher Aiken
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1.

Authors:  O Schwartz; V Maréchal; B Friguet; F Arenzana-Seisdedos; J M Heard
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

6.  Human tripartite motif 5alpha domains responsible for retrovirus restriction activity and specificity.

Authors:  David Perez-Caballero; Theodora Hatziioannou; Annie Yang; Simone Cowan; Paul D Bieniasz
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5alpha.

Authors:  Hassan Javanbakht; Felipe Diaz-Griffero; Matthew Stremlau; Zhihai Si; Joseph Sodroski
Journal:  J Biol Chem       Date:  2005-05-15       Impact factor: 5.157

8.  A dominant block to HIV-1 replication at reverse transcription in simian cells.

Authors:  Carsten Münk; Stephanie M Brandt; Ginger Lucero; Nathaniel R Landau
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-04       Impact factor: 11.205

9.  Restriction of lentivirus in monkeys.

Authors:  Caroline Besnier; Yasuhiro Takeuchi; Greg Towers
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-01       Impact factor: 11.205

10.  The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.

Authors:  Matthew Stremlau; Christopher M Owens; Michel J Perron; Michael Kiessling; Patrick Autissier; Joseph Sodroski
Journal:  Nature       Date:  2004-02-26       Impact factor: 49.962

View more
  96 in total

1.  RING domain mutations uncouple TRIM5α restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating.

Authors:  Amanda Roa; Fumiaki Hayashi; Yang Yang; Maritza Lienlaf; Jing Zhou; Jiong Shi; Satoru Watanabe; Takanori Kigawa; Shigeyuki Yokoyama; Christopher Aiken; Felipe Diaz-Griffero
Journal:  J Virol       Date:  2011-11-23       Impact factor: 5.103

2.  Hexagonal assembly of a restricting TRIM5alpha protein.

Authors:  Barbie K Ganser-Pornillos; Viswanathan Chandrasekaran; Owen Pornillos; Joseph G Sodroski; Wesley I Sundquist; Mark Yeager
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

3.  Proteasome inhibition reveals that a functional preintegration complex intermediate can be generated during restriction by diverse TRIM5 proteins.

Authors:  Jenny L Anderson; Edward M Campbell; Xiaolu Wu; Nick Vandegraaff; Alan Engelman; Thomas J Hope
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  How TRIM5alpha defends against retroviral invasions.

Authors:  Michael Emerman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-27       Impact factor: 11.205

Review 5.  HIV/AIDS epidemiology, pathogenesis, prevention, and treatment.

Authors:  Viviana Simon; David D Ho; Quarraisha Abdool Karim
Journal:  Lancet       Date:  2006-08-05       Impact factor: 79.321

Review 6.  Cyclophilin A, TRIM5, and resistance to human immunodeficiency virus type 1 infection.

Authors:  Jeremy Luban
Journal:  J Virol       Date:  2006-09-06       Impact factor: 5.103

7.  Isolation, characterization, and genetic complementation of a cellular mutant resistant to retroviral infection.

Authors:  Sumit Agarwal; Josephine Harada; Jeffrey Schreifels; Patrycja Lech; Bryan Nikolai; Tomoyuki Yamaguchi; Sumit K Chanda; Nikunj V Somia
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-16       Impact factor: 11.205

8.  The retroviral restriction factor TRIM5alpha.

Authors:  Sarah Sebastian; Jeremy Luban
Journal:  Curr Infect Dis Rep       Date:  2007-03       Impact factor: 3.725

9.  Determinants for the rhesus monkey TRIM5alpha-mediated block of the late phase of HIV-1 replication.

Authors:  Ryuta Sakuma; Seiga Ohmine; Yasuhiro Ikeda
Journal:  J Biol Chem       Date:  2009-12-01       Impact factor: 5.157

10.  Novel roles of cytoplasmic ICP0: proteasome-independent functions of the RING finger are required to block interferon-stimulated gene production but not to promote viral replication.

Authors:  Kathryne E Taylor; Marianne V Chew; Ali A Ashkar; Karen L Mossman
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.